FDA Approves Lazcluze (Lazertinib) Tablets for Non-Small Cell Lung Cancer Treatment
Lazcluze (Lazertinib) is the latest medical breakthrough in the ongoing fight against non-small cell lung cancer (NSCLC). Officially approved by the Food and Drug Administration (FDA) on August 19, 2024, Lazcluze offers a novel therapeutic option for patients diagnosed with this aggressive and often difficult-to-treat form of cancer. Its advent marks a significant milestone in … Read more